Antimutagenicity and induction of antioxidant defense by flavonoid rich extract of *Myrcia bella* Cambess. in normal and tumor gastric cells

Juliana Mara Serpeloni a,*, Ana Flávia Leal Specian b, Diego Luis Ribeiro b, Katiuska Tuttis b, Wagner Vilegas c, Wilner Martínez-López d, Anne Lígia Dokkedal e, Luiz Leonardo Saldanha e,f, Ilce Mara de Syllos Cólus b, Eliana Aparecida Varanda a

a Department of Botany, Institute of Bioscience, São Paulo State University (UNESP), Botucatu 18618-970, Brazil
b Department of General Biology, Center of Biological Sciences, State University of Londrina (UEL), Londrina 86057-970, Brazil
c Experimental Campus of São Vicente, São Paulo State University (UNESP), São Vicente 11350-000, Brazil
d Instituto de Investigaciones Biológicas Clemente Estable, Montevideo 11600, Uruguay
e Department of Biological Sciences, Faculty of Sciences, São Paulo State University (UNESP), Araraquara 14801-902, Brazil
f Department of Botany, Instituto de Biociências, São Paulo State University (UNESP), Botucatu 18618-970, Brazil

**Article info**

**Abstract**

**Ethnopharmacological relevance:** The Brazilian “Cerrado” is an important source of natural products, such as *Myrcia bella* Cambess (MB, also known as “mercurinho”). MB leaves are popularly used for the treatment of diabetes and gastrointestinal disorders; however, only its hypoglycemic activity has been experimentally described.

**Aim of the study:** Because MB is used to treat gastrointestinal disorders, the present study characterized biological activities of hydroalcoholic MB extract in human normal and tumor gastric cells.

**Materials and methods:** Cytotoxic, antiproliferative, genotoxic and protective effects were evaluated, as well as the effects of the MB extract on gene expression.

**Results:** The MB extract induced cytotoxicity in tumor cells at lower concentrations compared with normal cells as assessed by the MTT assay. Moreover, the MB extract induced necrosis based on acridine orange/ethidium bromide staining. An antiproliferative effect was evidenced through an arrest in the G2/M phase detected by flow cytometry and a decrease in the nuclear division index using the cytokinesis-block micronucleus cytome assay. Cells treated with MB extract combined with doxorubicin (DXR) showed increased NUBDs, which may be related to the gene amplification of CCND1. Antimutagenic effects were also observed and may be associated with the antioxidant activities detected using the CM-H2DCFDA probe.

**Conclusions:** Our findings showed the following: (a) high concentrations of MB induced cytotoxicity and cell death by necrosis; (b) its antiproliferative effect was associated with G2/M arrest; and (c) its antioxidant activity could be responsible for the observed antimutagenic effects and for protective effects against gastrointestinal disorders previously described to MB. Although these effects are not specific to normal or tumor cells, they provide a panel of biological activities for further exploration.

© 2015 Elsevier Ireland Ltd. All rights reserved.

1. Introduction

Currently, enormous efforts are focused on the analysis of plant extracts for use for medical purposes (Hammad et al., 2014). The *Myrcia* genus, which includes approximately 350 species, belongs to the subfamily Myrtoidea, Myrtaceae (Landrum and Kawasaki, 1997). Species of this genus are used in folk medicine in Brazil as astringents, diuretics, and coagulants, and for the treatment of diseases such as diabetes mellitus, hypertension and gastric ulcers (Hashimoto, 1996; Pepato et al., 1993; Russo et al., 1989). *Myrcia* spp. are typically found in the Brazilian savannah (the “Cerrado”), which is home to a large number of endemic species (Myers et al., 2000), including *Myrcia bella* Cambess. (MB).

The leaves of MB (also known as “mercurinho”) (Pott et al., 2006) has been used in Brazilian folk medicine for different purposes and are also exploited commercially as herbal drugs for the treatment of diabetes mellitus (Saldanha et al., 2013). A recent paper confirmed that extracts from MB leaves had hypoglycemic properties and possibly regulated glucose uptake by the liver.
with an aqueous extract of included antidiabetic activity. For example, diabetic rats treated of thyroid hormones by reducing thyroid peroxidase activity. The authors demonstrated that the *M. larutteana* and *M. obtecta* extracts had higher antioxidant activity compared to the flavonoid quercetin using the radical sequestration 2,2-diphenyl-1-picryl-hydrazyl (DPPH) test. The flavocarotene 2′,4′,6′-trihydroxycacetophenone (THA), an acetophenone isolated from *Myrcia multiflora*, also showed antioxidant activity in vitro and in vivo (Ferreira et al., 2010). Moreover, THA and other compounds isolated from *M. multiflora* demonstrated some pharmacological properties, such as hypolipidemic and anti-obesity activities (Ferreira et al., 2011). Ferreira et al. (2006) suggested that the chronic consumption of *M. uniflora* could induce hypothyroidism, especially in individuals who ingested small quantities of iodine and patients with thyroid dysfunction, because the compounds in the aqueous fraction of the methanol extract decreased the synthesis of thyroid hormones by reducing thyroid peroxidase activity.

The pharmacological activities related to the *Myrcia* spp. also included antidiabetic activity. For example, diabetic rats treated with an aqueous extract of *M. uniflora* showed improvement in metabolic parameters related to glucose homeostasis (Pepato et al., 1993). Rats treated with myricacitrins extracted from *M. multiflora* leaves showed a decrease in the activity of the enzyme aldose reductase; this enzyme catalyzes the reduction of glucose to sorbitol, representing the first step in glucose metabolism (Matsuda et al., 2002).

Considering that Brazilian people have used plants of *Myrcia* genus against disorders of the gastrointestinal tract (Hashimoto, 1996) and that only hypoglycemic activity was described to MB we performed a panel of toxicological tests to characterize the possible in vitro cytotoxic, antiproliferative, oxidant/antioxidant and mutagenic activities of the hydroalcoholic extract of MB leaves in normal and tumor (ACP02) human gastric cells. We also evaluated the protective effects of the extract against damage induced by the chemotherapeutic doxorubicin (DXR).

### 2. Material and methods

#### 2.1. Plant material

Samples of MB leaves from natural origins were collected at the Botanical Garden of Bauru-SP, Brazil (22°20′30″ S and 49°00′30″ W) in November, 2010. The plant name was verified with http://www.theplantlist.org. Voucher specimens were identified using macroscopic and microscopic methods by Prof. Dr. Anne L. Dokkedal and stored at the Herbarium of the São Paulo State University UNB (UNESP, SP, Brazil) under code number 5508. The standardized hydroalcoholic extract (EtOH 70%) used in the present study was produced via percolation and chemically characterized by HPLC-PDA-MS based analysis as described by Saldanha et al. (2013).

#### 2.2. Cell culture conditions

Tumor (ACP02) and normal human primary cells obtained by biopsy were provided by Prof. Dr. Rommel Burbano (Federal University of Pará, UFPA, Brazil) (Leal et al., 2009). Cells between the 3rd and 8th passage were defrosted and cultivated in Dulbecco’s Modified Eagle’s Medium (DMEM) high glucose plus 10% fetal bovine serum (FBS) (Gibco, Grand Island, NY, USA) and 1.0% penicillin and streptomycin (Sigma-Aldrich, St-Louis, MO, USA) in a 5% CO₂ atmosphere at 37 °C and 96% relative humidity. Three independent cultures were used to evaluate all parameters. The treatment medium was serum-free except for the assessment of the cell proliferation curves (Repetto et al., 2008). Positive (DXR 0.200 μg/mL, Sigma-Aldrich, St. Louis, MO, USA) and negative control groups (phosphate buffered saline-PBS) were included in the assays.

#### 2.3. MTT assays

MTT assays were conducted as described by Mosmann (1983) using 3-[4,5-Dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (CAS: 298-93-1, Sigma-Aldrich, St. Louis, MO, USA). Briefly, 1.0 × 10⁵ cells were seeded per well in a 96-well plate and exposed to MB extract (5.00–500 μg/mL) or DXR (0.05–250 μg/mL) for 24 h. The highest concentration of MB extract and DXR tested was based on their maximum dilution in PBS.

After 24 h of incubation, the cells were treated with MTT (0.50 mg/mL) and incubated for 4 h; then, 200 μL of DMSO were added to each well. Absorbances at 570 nm were measured on microplate spectrophotometers (Biotek Eon, Winooski, VT, USA). The results were expressed as the percentage of viable cells in relation to the negative control group (PBS).

#### 2.4. Cell proliferation curves

According to Seibert et al. (1996), cytotoxicity should be determined by using cell proliferation endpoint in which the time of exposure to treatment should be at least three time as long as the doubling time of the cells employed. For this reason, besides MTT assay we also employed cell proliferations curves where cells were treated for 5 days. A total of 2.5 × 10⁴ cells were seeded into a 24-well plate and exposed to two non-cytotoxic (5.00 and 100 μg/mL) and one cytotoxic (200 μg/mL) concentration of MB extract chosen from the MTT assay. The cells were harvested after 24, 48, 72, 96 and 120 h of treatment and 20 μL of the cell suspension was used for cell counting in a Neubauer chamber. Cell proliferation was evaluated by the total protein content using the method described by da Costa Lopes et al. (2000) and standardized in our laboratory (Ciliao et al., 2015). Results of MTT assay and cell proliferations curves were used to choose non-cytotoxic concentrations to be tested in next protocols.

#### 2.5. Cytokinesis-block micronucleus cytome assay (CBMN-cyt)

DNA instability was evaluated using CBMN-cyt according to the method of Fenech (2007). Briefly, 1.0 × 10⁶ cells were stabilized in 25 cm² culture flasks (Corning, Lowell, MA, USA) to test non-cytotoxic concentrations of MB extract (5.00, 50.0 or 100 μg/mL) and the controls. To evaluate the protective effects of the MB extract on DXR-induced DNA damage, the cells were treated with DXR associated to the MB extract (100 μg/mL) in protocols of pre-treatment (PRE), simultaneous (SIM) and post-treatment (POST). In PRE, cells were treated with MB for 24 h followed by 24 h of treatment with DXR. In POST, DXR was administered before the extract for the same time totaling 48 h of treatment. In SIM, DXR and MB extract were administered together during 24 h.

After treatments, the cultures were exposed to 3 μg/mL cyt-B (CAS: 14930-96-2, Sigma-Aldrich, St. Louis, MO, USA) for 30 h. The cells were harvested as described by Fenech (2007) using 1.0% sodium citrate as the hypotonic solution. After fixation, slides were prepared and stained with 5.0% Giemsa (CAS: 1.09204.0500, Merck®, Rio de Janeiro, RJ, Brazil) diluted in phosphate buffer (0.06 M Na₂HPO₄ and 0.06 M KH₂PO₄, pH 6.8) for 10 min, then
Table 1

<table>
<thead>
<tr>
<th>Gene</th>
<th>Sequence 5′-3′</th>
<th>Size of the amplification product (base pairs)</th>
</tr>
</thead>
<tbody>
<tr>
<td>MET</td>
<td>F: TACCCTCTATGCTGGT</td>
<td>201</td>
</tr>
<tr>
<td></td>
<td>R: CTCTGCTGCTGCTGTC</td>
<td></td>
</tr>
<tr>
<td>CCND1</td>
<td>F: CATGGAACCTCCTTCTCCA</td>
<td>140</td>
</tr>
<tr>
<td></td>
<td>R: AACTTCACATCTTGGCACC</td>
<td></td>
</tr>
<tr>
<td>BIRC5</td>
<td>F: GACCTGTGTTAGATGAGAG</td>
<td>138</td>
</tr>
<tr>
<td></td>
<td>R: TAGAATGGCTTCTTCTTAG</td>
<td></td>
</tr>
<tr>
<td>BAX</td>
<td>F: TTTGAGGCAACTTCACTGG</td>
<td>121</td>
</tr>
<tr>
<td></td>
<td>R: TGTCAGGCGATGCTTCTAG</td>
<td></td>
</tr>
<tr>
<td>BCL-XL</td>
<td>F: CAGCCAGAGGCAAAGG</td>
<td>132</td>
</tr>
<tr>
<td></td>
<td>R: GAGGCTAGGAGTGATGTC</td>
<td></td>
</tr>
<tr>
<td>TP53</td>
<td>F: CCATCCACTAACAATACAT</td>
<td>136</td>
</tr>
<tr>
<td></td>
<td>R: GCACAAACGGCACCTC</td>
<td></td>
</tr>
<tr>
<td>HPRT1</td>
<td>F: TCCTCTCTGCTGGCCACCG</td>
<td>101</td>
</tr>
<tr>
<td></td>
<td>R: TCTCTAAATCCAGCCAGCC</td>
<td></td>
</tr>
<tr>
<td>GAPDH</td>
<td>F: GGCGATCTGGGGTCTTACTC</td>
<td>208</td>
</tr>
<tr>
<td></td>
<td>R: CTTCAAGGTCGCTTAC</td>
<td></td>
</tr>
</tbody>
</table>

analyzed under a light microscopic (Nikon Eclipse E200, Tokyo, Japan) with 400x magnification. To score micronuclei (MNis), the frequencies of nucleoplasmatic bridges (NPBs) and nuclear buds (NBUDs), 3000 binucleated cells were analyzed per experimental point. A total of 1500 viable cells was scored to calculate the nuclear division index (NDI) using the formula described by Fenech (2007).

2.6. DNA content by flow cytometry analysis

Experimental protocols similar to those described above for CBMN-cyt were used for flow cytometry analysis with the inclusion of a cytotoxic MB concentration (200 μg/mL). Cells were trypsinized and centrifuged at 70 g for 5 min; then, the cell pellets were washed with PBS and centrifuged for an additional 5.0 min. The supernatant was removed and the pellet was re-suspended in 2.0 mL of ice-cold ethanol (70% in water; v/v). At the time of analysis, the cells were centrifuged; then, the ethanol was removed and the cells were re-suspended in 1.0 mL of PBS. The cells were centrifuged one more time, the supernatants were discarded and the cells were incubated in 200 μL of propidium iodide (PI) solution (10 mL PBS, 10 μL Triton, 100 μL RNase, and 40 μL of 1 mg/mL PI) for 30 min. After incubation, the samples were subjected to a fluorescence activated cell sorter (Becton Dickinson, Franklin Lake, NJ, USA). The data were analyzed using the Cell Quest software, and the cell cycle profiles were determined using the Flow Jo software (Tree Star Incorporation, Ashland, OR, USA).

2.7. Apoptosis/necrosis assays

The protocol described by McGahon et al. (1995) was applied to distinguish between viable, apoptotic and necrotic cells to enable the investigation into the mechanism involved in cell death. In total, 1.0 × 10⁶ cells were seeded into 12-well plates and treated for 1.0, 3.0, 6.0, 12 and 24 h with MB extract (5.00, 100, 200 and 400 μg/mL) and the controls. The cells were trypsinized, and 25 μL of the suspension was mixed with 1.0 μL of staining solution containing 100 μg/mL acidine orange (AO) and 100 μg/mL ethidium bromide (EB). A total of 600 cells was analyzed with a Nikon fluorescence microscope (Tokyo, Japan) using an excitation wavelength of 515–560 nm and a 590 nm barrier filter. The results were presented as the percentages of viable, apoptotic and necrotic cells.

2.8. Oxidant/antioxidant assay

Intracellular reactive species (RS) were measured using 5-(and-6)-chloromethyl-2′,7′-dichlorodihydrofluorescein diacetate, acetyl ester (CM-H₂DCFDA, Life technologies, Eugene, OR, USA). Cells were seeded into sterile black plates and exposed to 5.00, 100 or 200 μg/mL of MB extract for 1.0, 3.0, 6.0, 12 and 24 h with their respective controls. After treatments, the wells were washed with PBS; then, 100 μL of a 5 mM CM-H₂DCFDA solution was added and incubated for 30 min at 37 °C. Thereafter, 1 mM hydrogen peroxide (H₂O₂) was added for 15 min to the positive control group and simultaneous treatment group, followed by a wash with PBS. Finally, 100 μL of PBS were added to each well, and the absorbances were read on a Victor™ X3 multilabel plate reader (PerkinElmer, São Paulo, Brazil) at excitation k= 485 nm and emission k=528 nm. The results were presented as the fluorescence intensity.

2.9. Quantitative real-time polymerase chain-reaction (RT-qPCR)

The treatment protocols were the same as those employed in the CBMN-cyt assay using 5.00, 100 or 200 μg/mL of MB extract alone or 100 μg/mL MB extract in combination with DXR. Total RNA was extracted from the cells using the PureLink™ 100 μg/mL MB extract for 1.0, 3.0, 6.0, 12 and 24 h with their respective controls. After treatments, the wells were washed with PBS; then, 100 μL of a 5 mM CM-H₂DCFDA solution was added and incubated for 30 min at 37 °C. Thereafter, 1 mM hydrogen peroxide (H₂O₂) was added for 15 min to the positive control group and simultaneous treatment group, followed by a wash with PBS. Finally, 100 μL of PBS were added to each well, and the absorbances were read on a Victor™ X3 multilabel plate reader (PerkinElmer, São Paulo, Brazil) at excitation k= 485 nm and emission k=528 nm. The results were presented as the fluorescence intensity.

The treatment protocols were the same as those employed in the CBMN-cyt assay using 5.00, 100 or 200 μg/mL of MB extract alone or 100 μg/mL MB extract in combination with DXR.

![Fig. 1](image-url) Percentage of viable normal (dark gray columns) and gastric tumor (ACP02) (black columns) cells compared to the negative control group (PBS) after treatment with different concentrations of doxorubicin (0.05–2.50 μg/mL) in the MTT assay. Results represent the mean ± standard deviation of seven replicates. The negative control represents 100% of viability. PBS: phosphate buffered saline. *Significantly different from the negative control, ANOVA followed by Tukey’s test (p ≤ 0.05).
RNA Mini Kit (Life Technologies, Carlsbad, CA, USA). The quantity of RNA was determined by spectrophotometry (NanoDrop 2000C- Thermo Scientific, San Jose, CA, USA). RNA quality and integrity were assessed by electrophoresis in an agarose gel (Aranda et al., 2012). RNA samples were treated with DNase I (Amplification Grade, Invitrogen, Carlsbad, CA, USA) following the recommendations of the manufacturer.

The RNA was reverse-transcribed using the SuperScript III First Strand Synthesis System, Oligo-DT12-18 and random primers from Invitrogen (Carlsbad, CA, USA) following manufacturer’s protocol.

Reference genes were selected using the normalization program NormFinder. Primers for GAPDH (glyceraldehyde-3-phosphate dehydrogenase) and HPRT1 (hypoxanthine guanine phosphoribosyl transferase 1) as well as the genes of interest TP53 (tumor protein p53), CCND1 (cyclin D1), BAX (B-cell lymphoma 2-associated X protein), BCL-XL (B-cell lymphoma-extra-large), BIRC5 (Baculoviral inhibitor of apoptosis repeat containing 5) and MET (hepatocyte growth factor receptor) were generated using Gene Runner Software Version 3.05 (Spruyt and Buquicchio, 1994). Primer sequences are listed in Table 1. The primers for the CAT (catalase), GSR (glutathione reductase), GPx1 (glutathione peroxidase 1) and NFE2L2 (nuclear factor, erythroid 2-like 2) genes were obtained from the KicqStart® SYBR Green Primers (Sigma-Aldrich). The efficiency was determined by testing serial dilutions of cDNA until the best annealing temperature was obtained.

PCR runs were performed using the Techne Quantum™ Real Time PCR Cycler System (Staffordshire, UK) with the Platinum® SYBR® Green qPCR SuperMix UGD (Invitrogen, Carlsbad, CA, USA). The final volume was 10 µL and contained 20 pmol of each primer and 10 ng of the cDNA template. The reaction mixture was subjected to the following amplification program: 95 °C for 5 min, followed by 50 cycles of 95 °C for 15 s, 60 °C for 15 s and 72 °C for 30 s.

Fig. 2. Percentage of viable normal (white columns) and gastric tumor (ACP02) (gray columns) cells compared to the negative control group (PBS) after treatment with different concentrations of Myrcia bella extract (5.00–500 µg/mL) in the MTT assay. Results represent the mean ± standard deviation of seven replicates. The negative control represents 100% of viability. PBS: phosphate buffered saline. *Significantly different from the negative control, ANOVA followed by Tukey’s test (p ≤ 0.05).

Fig. 3. Proliferation curves of normal (a1 and b1) and tumor (ACP02) (a2 and b2) cells based on cell counts (a1 and a2) and quantification of total proteins (b1 and b2) after treatment with Myrcia bella extract (MB) compared to the negative (PBS) and positive control (DXR) groups. PBS: phosphate buffered saline; DXR: doxorubicin.
Table 2
Distribution of micronucleus (MNI) nuclear buds (NBUDs), nucleoplasmic bridges (NPBs), percentages of binucleated cells (BNB) and nuclear division indices (NDI) in normal and tumor gastric (ACP02) cells treated with different concentrations of the extract of Myrcia bela (MB) alone and in combination with DXR (0.200 μg/mL) in the experimental protocols of pre-treatment (PRE), simultaneous (SIM) and post-treatment (POST) compared to the respective negative (PBS) and positive (DXR 0.200 μg/mL) control groups.

<table>
<thead>
<tr>
<th>TREATMENTS</th>
<th>PARAMETERS studied</th>
<th>PBS 0.0</th>
<th>ACP02</th>
<th>PBS 0.0</th>
<th>ACP02</th>
<th>PBS 0.0</th>
<th>ACP02</th>
<th>PBS 0.0</th>
<th>ACP02</th>
<th>PBS 0.0</th>
<th>ACP02</th>
<th>PBS 0.0</th>
<th>ACP02</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>MN</td>
<td>6.0±0.5</td>
<td>5.8±0.5</td>
<td>5.7±0.5</td>
<td>5.6±0.5</td>
<td>5.6±0.5</td>
<td>5.5±0.5</td>
<td>5.6±0.5</td>
<td>5.6±0.5</td>
<td>5.6±0.5</td>
<td>5.6±0.5</td>
<td>5.6±0.5</td>
<td>5.6±0.5</td>
</tr>
<tr>
<td></td>
<td>NUBDs</td>
<td>0.7±0.2</td>
<td>0.6±0.2</td>
<td>0.6±0.2</td>
<td>0.6±0.2</td>
<td>0.6±0.2</td>
<td>0.6±0.2</td>
<td>0.6±0.2</td>
<td>0.6±0.2</td>
<td>0.6±0.2</td>
<td>0.6±0.2</td>
<td>0.6±0.2</td>
<td>0.6±0.2</td>
</tr>
<tr>
<td></td>
<td>NPBs</td>
<td>2.0±0.1</td>
<td>2.0±0.1</td>
<td>2.0±0.1</td>
<td>2.0±0.1</td>
<td>2.0±0.1</td>
<td>2.0±0.1</td>
<td>2.0±0.1</td>
<td>2.0±0.1</td>
<td>2.0±0.1</td>
<td>2.0±0.1</td>
<td>2.0±0.1</td>
<td>2.0±0.1</td>
</tr>
<tr>
<td></td>
<td>%BN</td>
<td>8.0±1.0</td>
<td>8.0±1.0</td>
<td>8.0±1.0</td>
<td>8.0±1.0</td>
<td>8.0±1.0</td>
<td>8.0±1.0</td>
<td>8.0±1.0</td>
<td>8.0±1.0</td>
<td>8.0±1.0</td>
<td>8.0±1.0</td>
<td>8.0±1.0</td>
<td>8.0±1.0</td>
</tr>
<tr>
<td></td>
<td>NDI</td>
<td>3.0±0.0</td>
<td>3.0±0.0</td>
<td>3.0±0.0</td>
<td>3.0±0.0</td>
<td>3.0±0.0</td>
<td>3.0±0.0</td>
<td>3.0±0.0</td>
<td>3.0±0.0</td>
<td>3.0±0.0</td>
<td>3.0±0.0</td>
<td>3.0±0.0</td>
<td>3.0±0.0</td>
</tr>
</tbody>
</table>

A total of 3000 binucleated cells were analyzed per group for all parameters except NDI (1500 cells per group). NDI=(N1+N2)/3+N3); N1-N4=number of cells with 1, 2, 3 or 4 nuclei, N=total of cells analyzed. PBS: phosphate buffered saline; DXR: doxorubicin. The data represent the mean ± SD (standard deviation) of three independent experiments.

*Significantly different from the positive control group (p<0.05). ANOVA and Tukey’s test.

15 s. Finally, a melting curve was generated in the range of 50–95 °C.

Gene expression data were analyzed with the Quantsoft V.1.1.30‡ Software (Staffordshire, UK) and normalized using the cycle threshold (Ct) for each sample in the linear region of the amplification plot. GAPDH and HPRT1 genes were selected to normalize target gene expression. Relative quantification of gene expression was calculated according to Pfaffl (2001).

2.10. Statistical analysis

One-way analysis of variance (ANOVA) followed by Tukey’s test was performed with the GraphPad Prism 5® software system (La Jolla, CA, USA). All data are presented as mean ± standard deviation with p<0.05.

Changes in gene expression were compared to the control situation and considered to be significantly different when p<0.05.

3. Results

3.1. MTT assay

The results obtained from the MTT assay after treatment of the cells with DXR and the MB extract are presented in Figs. 1 and 2, respectively. Only tumor gastric cells exhibited decreased cell viability after treatment with DXR (Fig. 1) at concentrations equal or higher than 1.00 μg/mL. Fig. 2 shows that no cytotoxic effects were seen when normal (white columns) and ACP02 tumor cells (gray columns) were exposed to the MB extract in doses up to 200 μg/mL and up to 150 μg/mL, respectively. These results indicated that concentrations of 0.200 μg/mL for DXR and doses up to 150 μg/mL for the MB extract were non-cytotoxic; these concentrations were applied in the following assays.

3.2. Cell proliferation curves

Cell proliferation curves were performed to assess the cytotoxic and non-cytotoxic concentrations of the MB extract obtained from the MTT assay (Fig. 3). Exposure to the cytotoxic concentration of the MB extract (200 μg/mL) reduced cell growth, as demonstrated by the curves of cell counts (3a) and protein content (3b) for non-cytotoxic concentrations of the MB extract obtained from 150 μg/mL and up to 150 μg/mL for the MB extract were non-cytotoxic; these concentrations were applied in the following assays.

3.3. CBMN cyt

The results obtained from the analysis of MNI, NPBs and NBUDs in binucleated cells that reflect the possible mutagenic and antimutagenic activity of the MB extract are presented in Table 2. The MN induction factor (IF) in cells treated with MB extract was similar to the negative control group, while the IF was 3.67 in cells treated with DXR. Only the highest concentration of MB extract (100 μg/mL) changed the frequency of NBUDs in tumor cells (Table 2). Neither MNI nor NPBs was altered in either cell line after treatment with different concentrations of the MB extract.

The highest concentration (100 μg/mL) decreased the NDI in
both cell types relative to the control group. This decrease was more evident in normal cells, with 100 μg/mL of MB extract inducing a strong antiproliferative effect that made it impossible to analyze the CBMN-cyt parameters. The MB extract concentration of 100 μg/mL was chosen to evaluate the antimutagenicity, because this concentration did not show mutagenic effects. In both cell types, the association of MB extract with DXR in the PRE protocol decreased cell proliferation to levels that made the scoring of MNi, NPBs and NBUDs impossible. Interestingly, this phenomenon was not observed when the SIM and POST experimental protocols were used (Table 2). Moreover, protective effects were observed only when the cells were exposed simultaneously to MB extract and DXR in both cell lines. MB extract reduced DNA damage by 54% and 52% in the normal and tumor cells lines, respectively.

3.4. DNA content analysis by flow cytometry

The antiproliferative effects of the MB extract may be the result of changes in the cell cycle. Thus, the effect of MB on the cell cycle was assessed for both cell lines. The results of the flow cytometry analysis after treatment with different concentrations of MB extract (5.00, 100 and 200 μg/mL) are shown in Fig. 4; Fig. 4a1 and a2 shows data obtained with normal cells and Fig. 4b1 and b2 shows data obtained with tumor cells. Only the highest concentration of MB extract was cytotoxic in normal gastric cells, as evidenced by the increase in the SubG1 cell population. DXR and all extract concentrations induced an arrest in the G2/M and S phases of tumor cells. This result was observed only for the 100 and 200 μg/mL extract concentrations in normal cells.

Similar to the results observed in the CBMN-cyt assay, pre-treatment of the cells induced a strong arrest in the G2/M and S phases.

3.5. Apoptosis/necrosis assay

Next, we investigated the mechanisms involved in the cytotoxic effects of the MB extract. Results observed after 1.0, 3.0, 6.0, 12 and 24 h of treatment of normal and tumor cells are presented in Table 3. In general, concentrations that had previously demonstrated cytotoxic effects in the MIT and cell proliferation curves (200 and 400 μg/mL) induced cell death by necrosis in both cell types, even after only one hour of treatment. Moreover, this necrotic effect increased following longer treatment times, with the highest concentration of the MB extract (400 μg/mL) resulting in the death of all normal gastric cells after 3 h of treatment. This strong cytotoxic effect made impossible the counting of cells.

DXR induced cell death only in tumor cells by apoptosis after 3.0 or 6.0 h of treatment and by necrosis after 24 h.

3.6. Oxidant/antioxidant evaluation

The quantification of reactive species in normal and tumor cells is shown in Fig. 5a and b, respectively. The absorbance obtained...
Table 3
Frequency of viable, apoptotic and necrotic gastric tumor cells treated with *Myrcia bella* extract (MB) at different concentrations (5.00, 100, 200 and 400 µg/mL) and their respective negative (PBS) and positive (DXR 0.200 µg/mL) controls.

<table>
<thead>
<tr>
<th>Time of Treatment</th>
<th>PBS</th>
<th>ACP02</th>
<th>PBS</th>
<th>ACP02</th>
<th>PBS</th>
<th>ACP02</th>
<th>PBS</th>
<th>ACP02</th>
<th>PBS</th>
<th>ACP02</th>
<th>PBS</th>
<th>ACP02</th>
</tr>
</thead>
<tbody>
<tr>
<td>V</td>
<td>95.5 ± 1.41</td>
<td>89.50 ± 3.54</td>
<td>95.00 ± 1.41</td>
<td>87.00 ± 0.00</td>
<td>97.00 ± 0.00</td>
<td>91.50 ± 0.71</td>
<td>85.00 ± 4.24</td>
<td>91.00 ± 1.41</td>
<td>85.00 ± 4.24</td>
<td>75.50 ± 2.12</td>
<td>27.00 ± 2.83</td>
<td>78.50 ± 4.24</td>
</tr>
<tr>
<td>A</td>
<td>1.50 ± 0.00</td>
<td>5.00 ± 2.83</td>
<td>2.75 ± 2.12</td>
<td>8.50 ± 3.54</td>
<td>1.75 ± 0.71</td>
<td>6.00 ± 1.41</td>
<td>1.50 ± 1.41</td>
<td>6.50 ± 2.12</td>
<td>1.50 ± 1.41</td>
<td>2.50 ± 0.71</td>
<td>2.00 ± 0.00</td>
<td>3.50 ± 2.12</td>
</tr>
<tr>
<td>N</td>
<td>3.00 ± 1.41</td>
<td>5.50 ± 0.71</td>
<td>2.25 ± 0.70</td>
<td>4.50 ± 3.54</td>
<td>1.25 ± 0.71</td>
<td>2.50 ± 0.71</td>
<td>13.50 ± 5.66</td>
<td>2.50 ± 0.71</td>
<td>13.50 ± 5.66</td>
<td>22.00 ± 1.41</td>
<td>71.00 ± 2.83</td>
<td>18.00 ± 1.41</td>
</tr>
<tr>
<td>V</td>
<td>94.75 ± 2.12</td>
<td>92.00 ± 4.24</td>
<td>96.00 ± 1.41</td>
<td>86.50 ± 0.71</td>
<td>96.25 ± 2.12</td>
<td>93.5 ± 2.12</td>
<td>92.25 ± 2.12</td>
<td>93.5 ± 2.12</td>
<td>96.00 ± 4.24</td>
<td>89.50 ± 0.71</td>
<td>NA</td>
<td>70.50 ± 4.95</td>
</tr>
<tr>
<td>A</td>
<td>1.50 ± 0.00</td>
<td>6.00 ± 1.41</td>
<td>1.75 ± 0.71</td>
<td>11.00 ± 0.00</td>
<td>1.00 ± 0.00</td>
<td>5.50 ± 2.12</td>
<td>1.25 ± 0.71</td>
<td>5.00 ± 0.00</td>
<td>1.00 ± 0.00</td>
<td>1.00 ± 0.00</td>
<td>NA</td>
<td>3.50 ± 3.54</td>
</tr>
<tr>
<td>N</td>
<td>3.75 ± 2.12</td>
<td>2.00 ± 2.83</td>
<td>2.25 ± 0.71</td>
<td>2.50 ± 0.71</td>
<td>2.75 ± 2.12</td>
<td>1.00 ± 0.00</td>
<td>6.50 ± 1.41</td>
<td>1.50 ± 0.71</td>
<td>13.00 ± 4.24</td>
<td>9.50 ± 1.71</td>
<td>NA</td>
<td>26.00 ± 8.49</td>
</tr>
<tr>
<td>V</td>
<td>95.50 ± 1.41</td>
<td>90.00 ± 0.90</td>
<td>91.50 ± 0.00</td>
<td>92.00 ± 1.41</td>
<td>96.25 ± 4.95</td>
<td>96.00 ± 1.41</td>
<td>90.0 ± 1.41</td>
<td>90.50 ± 0.71</td>
<td>85.25 ± 12.02</td>
<td>77.00 ± 2.83</td>
<td>NA</td>
<td>51.00 ± 1.41</td>
</tr>
<tr>
<td>A</td>
<td>1.00 ± 0.00</td>
<td>5.50 ± 0.71</td>
<td>4.75 ± 2.12</td>
<td>6.00 ± 1.41</td>
<td>2.00 ± 4.24</td>
<td>2.50 ± 0.71</td>
<td>10.00 ± 0.00</td>
<td>2.00 ± 0.00</td>
<td>1.25 ± 0.71</td>
<td>3.50 ± 0.71</td>
<td>NA</td>
<td>3.00 ± 2.83</td>
</tr>
<tr>
<td>N</td>
<td>3.50 ± 1.41</td>
<td>4.50 ± 0.00</td>
<td>3.75 ± 2.12</td>
<td>2.00 ± 0.00</td>
<td>1.75 ± 0.71</td>
<td>1.50 ± 0.71</td>
<td>9.00 ± 1.41</td>
<td>7.50 ± 0.71</td>
<td>13.50 ± 11.31</td>
<td>19.50 ± 2.12</td>
<td>NA</td>
<td>46.00 ± 1.41</td>
</tr>
<tr>
<td>V</td>
<td>96.75 ± 0.71</td>
<td>90.50 ± 0.71</td>
<td>92.75 ± 0.71</td>
<td>87.00 ± 2.83</td>
<td>96.25 ± 0.71</td>
<td>91.00 ± 1.41</td>
<td>89.00 ± 8.49</td>
<td>90.00 ± 1.41</td>
<td>61.50 ± 14.14</td>
<td>85.50 ± 0.71</td>
<td>NA</td>
<td>78.00 ± 5.66</td>
</tr>
<tr>
<td>A</td>
<td>1.00 ± 0.00</td>
<td>7.50 ± 0.71</td>
<td>5.25 ± 0.71</td>
<td>8.00 ± 1.41</td>
<td>1.75 ± 2.12</td>
<td>6.00 ± 1.41</td>
<td>1.25 ± 0.71</td>
<td>2.50 ± 0.71</td>
<td>0.75 ± 0.71</td>
<td>3.00 ± 0.00</td>
<td>NA</td>
<td>1.50 ± 0.71</td>
</tr>
<tr>
<td>N</td>
<td>2.25 ± 0.71</td>
<td>2.00 ± 0.00</td>
<td>2.00 ± 0.00</td>
<td>5.00 ± 1.41</td>
<td>2.00 ± 1.41</td>
<td>3.00 ± 0.00</td>
<td>9.75 ± 7.78</td>
<td>7.50 ± 0.71</td>
<td>37.50 ± 13.44</td>
<td>11.50 ± 0.71</td>
<td>NA</td>
<td>20.50 ± 0.71</td>
</tr>
<tr>
<td>V</td>
<td>94.75 ± 0.71</td>
<td>93.50 ± 0.71</td>
<td>86.00 ± 5.66</td>
<td>88.50 ± 0.71</td>
<td>95.50 ± 1.41</td>
<td>92.50 ± 2.12</td>
<td>87.50 ± 7.07</td>
<td>91.00 ± 1.41</td>
<td>61.50 ± 4.24</td>
<td>73.50 ± 0.71</td>
<td>NA</td>
<td>53.50 ± 2.12</td>
</tr>
<tr>
<td>A</td>
<td>2.00 ± 0.00</td>
<td>6.00 ± 0.00</td>
<td>8.75 ± 0.71</td>
<td>6.50 ± 1.41</td>
<td>2.00 ± 0.00</td>
<td>4.50 ± 0.71</td>
<td>1.75 ± 2.12</td>
<td>1.50 ± 2.12</td>
<td>1.00 ± 0.00</td>
<td>2.50 ± 0.71</td>
<td>NA</td>
<td>0.50 ± 0.71</td>
</tr>
<tr>
<td>N</td>
<td>3.25 ± 0.71</td>
<td>0.50 ± 0.71</td>
<td>5.25 ± 4.95</td>
<td>5.00 ± 0.00</td>
<td>2.50 ± 1.41</td>
<td>3.00 ± 0.71</td>
<td>10.75 ± 4.95</td>
<td>7.50 ± 0.71</td>
<td>37.50 ± 11.31</td>
<td>24.00 ± 1.41</td>
<td>NA</td>
<td>46.00 ± 2.83</td>
</tr>
</tbody>
</table>

Cells were sampled at 1.0, 3.0, 6.0, 12 and 24 h after treatment. PBS: phosphate buffered saline. DXR: doxorubicin. NA: not analyzed (treatments where it was impossible to count the cells due to high cytotoxicity).

* Significantly different from the negative control group (PBS), ANOVA and Tukey’s test (*p* ≤ 0.05).
after treatment with different MB extract concentrations were compared to cells treated with PBS to evaluate the oxidant activity and to cells treated with PBS + H2O2 to evaluate antioxidant activity. None of the concentrations of MB extract tested showed an oxidant effect in normal cells. However, in tumor cells, the 200 mg/mL concentration induced an oxidant effect at all-time points, while the 100 mg/mL concentration showed an oxidant effect at 12 and 24 h.

Antioxidant effects were observed in both cell types at every treatment time point. However, the reduction in the intensity of fluorescence was more evident in the normal compared to the tumor cells.

3.7. Gene expression analysis

Finally, we analyzed gene expression using RT-qPCR (Fig. 6) in normal (Fig. 6a1) and tumor gastric cells (Fig. 6b1 and b2).

The expression levels of the genes TP53, BAX, BCL-XL, BIRC5, MET, CAT, GSR and GPx1 were not modulated by DXR or MB extract alone or in combination. The expression of the proto-oncogene CCND1 increased in the combined treatment protocols (MB + DXR) in both cell types. Furthermore, the expression of NFE2L2 decreased in tumor cells treated with the cytotoxic concentration of the extract (MB 200 μg/mL).

4. Discussion

Plant extracts remain an important source of studies related to the prevention and treatment of diseases. Promising results in the evaluation of crude plant extracts directed the search towards the active components responsible for their biological and pharmacological activities. In some cases, the interaction among bioactive compounds in the extract is responsible for its biological activity (Hammad et al., 2014). Thus, it is logical to investigate crude extracts in the search for biological activities prior to testing their bioactive compounds individually.

Some bioactive components from plants showed anticancer activities (Wang et al., 2012). Crude vegetal extracts have also been investigated concerning their anticancer properties (Jeong et al., 2015; Tai et al., 2014; Xu et al., 2013). The biological activities of the Myrcia bella extract were investigated even though promising results were found for another species of this genus.

In the present study, we evaluated possible cytotoxic effects by assessing the effect of a range of extract concentrations in normal and tumor cells (ACP02). Tumor cells were more sensitive than normal cells. Thus, it is important to select concentrations that kill tumor cells, but do not induce disturbances in the homeostasis of healthy cells. The AO/BE test demonstrated that cytotoxic concentrations (200 and 400 μg/mL) killed both type of cell lines (normal and tumor) by inducing the necrosis process instead of apoptosis.

The MTT assay detects alterations in mitochondrial integrity and its capacity to exert its cellular functions (Bernhard et al., 2003); however, this test did not detect changes in cell proliferation. For these reason, we generated cell proliferation curves. Importantly, in contrast to the cytotoxic effects that were detected only in tumor cells at the concentration of 200 μg/mL after 24 h of treatment in the MTT assay, the same concentration exhibited an anti-proliferative capacity in both cell types when longer time periods were analyzed using the cell proliferation curves. This anti-proliferative effect was studied in more detail in the NDI evaluation.
Antimutagenic effects were observed in both cell lines in the CBMN-cyt assays when the cells were treated with the MB extract plus DXR. This antimutagenic property associated with the recently described hypoglycemic activity (Vareda et al., 2014) encourages the search for beneficial activities of the MB extract at concentrations that do not induce cytotoxic effects. Based on the NDI results, the PRE treatments involving combination of the MB extract and DXR had a strong antiproliferative effect. This effect was so strong in normal cells that the analysis of the CBMN-cyt parameters was not possible. In agreement with this finding, the cell cycle analysis showed an increase in the Sub-G1 population in this same treatment group, but only in normal cells.

Antimutagens include compounds that have different mechanisms of action, including antioxidant activity (Sloczynska et al., 2014). The results obtained using the CM-H$_2$DCFDA probe suggest that the antimutagenic activity could be related to the observed antioxidant effect. Because the MB extract was administered prior to the induction of reactive species by H$_2$O$_2$, some compounds in the extract could have removed these species before they reacted with the DNA and induced DNA damage (Lee et al., 2011). A direct antioxidant effect of MB was supported by the RT-qPCR results that showed that cells did not present alterations in the expression patterns of antioxidant genes. A reduction in NFE2L2 expression was observed in tumor cells when the MB extract was combined with DXR; this result indicated that this DNA protection pathway was not impaired in normal cells. Several studies have correlated gastrointestinal diseases with inflammation and increased oxidative stress (Ock et al., 2012; Suzuki et al., 2012). Suzuki et al. (2012) noted that the use of antioxidants was important to increase the antioxidant and anti-inflammatory capacity and prevent the onset of gastrointestinal disorders. Given our results, the antioxidant activity of the MB extract could be linked to the traditional use of MB against diseases of the gastrointestinal tract.

The present study demonstrated that the NUBD frequency after treatment with the MB extract in combination with DXR in a simultaneous experimental protocol in normal and tumor cells was higher compared to the control cells. One mechanism involved in NUBDs formation is gene amplification (Fenech et al., 2011) and/or removal of DNA repair complexes (Chua et al., 2014). Our results cannot identify which gene is amplified, but one hypothesis is that the overexpression of different genes may be related to increases in the NUBDs frequency, including CCND1 that had its expression increased approximately five-fold in both cell lines. We also propose that the increased CCND1 expression could represent a strategy used by the cells to repair the damage induced by DXR; in support of these findings, Jirawatnotai et al. (2012) previously revised the role of the CCND1 protein in the process of DNA repair.

It is possible to try to explain the observed effects based on the chemical composition of the MB extract. HPLC-PDA-MS based analysis (data not shown) confirms the presence of flavonoids and phenolic acids derivatives in MB extract used in this study. In a recent paper from our research group (Saldanha et al., 2013) regarding the chemical composition of MB, we showed that its main constituents were flavonoid aglycones, flavonoid-O-glycosides, and acylated flavonoid-O-glycoside derivatives of quercetin and myricetin. Depending on the concentration tested, these compounds may exhibit cytotoxic and pro-oxidant activities (Heeba and Mahmoud, 2014; Zhang et al., 2009). Other interesting results observed with the MB extract are the antimutagenic and antioxidant properties that were also demonstrated for quercetin and myricetin (Barcelos et al., 2011; Chen et al., 2011; Hayden et al., 2008; Mladenovic et al., 2013).

The antiproliferative capacity was the most obvious biological effect observed in this work; strategies involving the inhibition of cell cycle progression have been extensively evaluated in order to...
manage the progression of tumors (Schwartz and Shah, 2005). Zhang et al. (2009) demonstrated that quercetin and myricetin were able to induce cell cycle arrest in the G2/M phase in another gastrointestinal tract cell line (the esophageal squamous cell carcinoma cell line KYSE-510). Several studies demonstrated the capacity of quercetin (Berndt et al., 2013; Choi et al., 2001; Li et al., 2014) and myricetin (Sun et al., 2012; Wang et al., 2004; Zhang et al., 2011) to induce G2/M arrest in different cell types. Haddad et al. (2006) demonstrated that different flavonoids exerted their antiproliferative effects at lower doses in prostate cancer cells compared to normal prostate cells. We observed an inverse effect in the present work, because even the lowest concentrations of the MB extract evaluated induced G2/M arrest in normal cells but not in tumor cells.

In summary, the mutagenic effect observed through the increase in NUBDs formation in tumor cells may be related to the oxidative stress observed in these cells and the gene amplification of the CCND1 gene. Moreover, the cell cycle arrest in the G2/M phase could be related to the observed antiproliferative results. The antioxidant effects demonstrated using the CM-H2DCFDA probe were most likely responsible for the antimutagenic effects observed in both cell types. Importantly, we provided a wide characterization of the biological effects of the MB extract, a first step to establish a new phytotherapeutic agent. We also showed that its antioxidant capacity, besides not selective, could be responsible for the protective effects against gastrointestinal disorders observed in the traditional use of MB by Brazilian population.

Conflict of interest statement

The authors have declared no conflict of interest.

Acknowledgments

We are grateful to Heloisa Lizotti Cilião (Universidade Estadual de Londrina) for her technical assistance and Hellen Kuanse (A. C. Camargo Cancer Center) for her technical assistance with the gene expression analysis. Juliana Mara Serpeloni was sponsored by a fellowship from Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP). Process no. 2012/01996-0. The entire project was also supported by FAPESP. Process no. 2009/52237-9.

References


In summary, the mutagenic effect observed through the increase in NUBDs formation in tumor cells may be related to the oxidative stress observed in these cells and the gene amplification of the CCND1 gene. Moreover, the cell cycle arrest in the G2/M phase could be related to the observed antiproliferative results. The antioxidant effects demonstrated using the CM-H2DCFDA probe were most likely responsible for the antimutagenic effects observed in both cell types. Importantly, we provided a wide characterization of the biological effects of the MB extract, a first step to establish a new phytotherapeutic agent. We also showed that its antioxidant capacity, besides not selective, could be responsible for the protective effects against gastrointestinal disorders observed in the traditional use of MB by Brazilian population.

Conflict of interest statement

The authors have declared no conflict of interest.

Acknowledgments

We are grateful to Heloisa Lizotti Cilião (Universidade Estadual de Londrina) for her technical assistance and Hellen Kuanse (A. C. Camargo Cancer Center) for her technical assistance with the gene expression analysis. Juliana Mara Serpeloni was sponsored by a fellowship from Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP). Process no. 2012/01996-0. The entire project was also supported by FAPESP. Process no. 2009/52237-9.

References


In summary, the mutagenic effect observed through the increase in NUBDs formation in tumor cells may be related to the oxidative stress observed in these cells and the gene amplification of the CCND1 gene. Moreover, the cell cycle arrest in the G2/M phase could be related to the observed antiproliferative results. The antioxidant effects demonstrated using the CM-H2DCFDA probe were most likely responsible for the antimutagenic effects observed in both cell types. Importantly, we provided a wide characterization of the biological effects of the MB extract, a first step to establish a new phytotherapeutic agent. We also showed that its antioxidant capacity, besides not selective, could be responsible for the protective effects against gastrointestinal disorders observed in the traditional use of MB by Brazilian population.

Conflict of interest statement

The authors have declared no conflict of interest.

Acknowledgments

We are grateful to Heloisa Lizotti Cilião (Universidade Estadual de Londrina) for her technical assistance and Hellen Kuanse (A. C. Camargo Cancer Center) for her technical assistance with the gene expression analysis. Juliana Mara Serpeloni was sponsored by a fellowship from Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP). Process no. 2012/01996-0. The entire project was also supported by FAPESP. Process no. 2009/52237-9.
Saldanha, L.L., Vilegas, W., Dokkedal, A.L., 2013. Characterization of flavonoids and phenolic acids in Myrcia bella Cambess. using FIA-ESI-IT-MS(n) and HPLC-PAD-ESI-IT-MS combined with NMR. Molecules 18, 8402–8416.